← Eichor
Condition: Mrd Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mrd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06426511NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425Risk Stratification and MRD-driven Maintenance for MM After ASCT
NA · 4 location(s) · Peking University People's Hospital · NCT06697483Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · 1 location(s) · University of Illinois at Chicago · NCT05192122IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Phase 2 · 1 location(s) · Dickran Kazandjian, MD · NCT06376526Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Multi-center MRD Registry for Inflammatory Breast Cancer
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT06966050Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Le
Phase 2 · 15 location(s) · Goethe University · NCT06648889ctDNA-MRD Monitoring After Resection in Gastric Cancer
Phase N/A · 1 location(s) · Peking University · NCT06893133MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer
NA · 1 location(s) · Sun Yat-sen University · NCT06204484Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Phase 2 · 1 location(s) · Sheng-Li Xue, MD · NCT05940961Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Phase 2 · 6 location(s) · Hyoung Jin Kang · NCT06257394Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Phase 2 · 2 location(s) · Guangdong Association of Clinical Trials · NCT07120698Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Phase N/A · 7 location(s) · Zhujiang Hospital · NCT06157060Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Phase N/A · 6 location(s) · University Medical Center Groningen · NCT06111807Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Phase 3 · 48 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04168502Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Phase 2/Phase 3 · 1 location(s) · Second Affiliated Hospital of Wenzhou Medical University · NCT06341907Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07291921Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06144606Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · University of California, San Diego · NCT06711705
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.